Riva Medical

Riva Medical, Inc. is a privately held medical device company headquartered in Los Gatos, California. The company was co-founded in 2008 by CEO Ted Moon. Prior to establishing Riva Medical, Moon had an extensive career in the medical device industry, including serving as President and CEO of Micrus Endovascular, which was acquired by Johnson & Johnson. This background in leading and successfully exiting a medical technology company provided a strong foundation for his new venture.

Riva Medical is focused on the development of innovative stent technologies for the treatment of vascular disease. The company operates within the interventional cardiology and radiology market, targeting physicians and healthcare systems that perform procedures to treat blockages in arteries. Its core product is a bioresorbable stent, which is a temporary scaffold designed to support a blood vessel and then gradually dissolve over time after the vessel has healed. This approach aims to eliminate the long-term complications associated with permanent metallic stents, such as chronic inflammation or late-stent thrombosis.

The company's proprietary technology is centered around its biomaterials. Riva Medical has developed a unique bioabsorbable polymer called Tyrocore™, which is derived from tyrosine, an amino acid naturally found in the body. This material is engineered for strength and radiopacity, meaning it is visible under X-ray, a feature that aids physicians during placement. The company's first-generation product, the FANTOM® bioresorbable scaffold, received CE Mark approval, allowing it to be marketed in Europe. Following this, Riva developed its second-generation product, the MOTIV® sirolimus-eluting bioresorbable scaffold, which also gained CE Mark approval in 2020 for treating peripheral artery disease, specifically below the knee. The MOTIV scaffold is designed to provide vessel support for about nine months before fully resorbing within 24 months.

Keywords: bioresorbable scaffold, peripheral artery disease, interventional cardiology, medical device, Tyrocore, sirolimus-eluting, vascular disease, stent technology, CE Mark, medtech